DDInter899 DDInter1698
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved
Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020.
Somapacitan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Somapacitan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Somapacitan {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Somapacitan may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Dapsone
Somapacitan may lead to a major life threatening interaction when taken with Bexarotene